BREAKING NEWS from ADA 2021

This page was last updated at 11:11 am EST June 28, 2021.

Editor’s Note: This article will be updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Check back often! Follow along with us on Twitter at #ADA2021. Coverage of the ADA Scientific Sessions is brought to you by the ADA x BT1 Collab.

SUNDAY, JUNE 27, 2021

  • Results from DARE-19, the first large randomized clinical trial to assess (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19 showed that Dapagliflozin is well tolerated.
  • In an early morning session at ADA titled “Who Should Loop?”, providers and patients gave perspectives on the current state of DIY Looping systems in 2021 and discussed the pros and cons of the various systems.
  • A discussion about the progression of Type 2 diabetes in children/youth (aged 10-19) showed that compared to adults: diabetes in children is more aggressive, beta-cell function decreases faster even with medications, and complications such as retinopathy and cardiovascular issues are accelerated and usually found at diagnosis. The discussion also discussed new and ongoing trials to increase the chances of approval of the use of Type 2 diabetes, typically used for adults, for children.

SATURDAY, JUNE 26, 2021

FRIDAY, JUNE 25, 2021

THURSDAY, JUNE 24, 2021

1 Like

While reading the 1st link, I then found following link related to Medicare coverage for CGMS coverage. (Making more available)

Odd that its dated in future !!

2 Likes

I suspect that the future date is likely a typo and that the event cited actually occurred in 2020.

Good to see that the Medicare rules have relaxed and will allow more people to use this effective tool.

1 Like